Today, February 4th, we celebrate a key international cancer awareness day, World Cancer Day2024. The Day aims to raise awareness of cancer research, to remove the stigma ‘’sentenced-to-death’’ from cancer patients, and to remind policy-makers that #cancer is not a silent menace. On the contrary, in many cases, #cancer is a manageable, treatable disease if adequate prevention and education measures are implemented and when access to medicines is enabled.
World Cancer Day was established by the Paris Charter adopted at the World Summit Against Cancer for the New Millenium in Paris on 4 February 2000.
Read it here
According to the International Agency for Research on Cancer (IARC), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease.
Read more
IARC’s Global Cancer Observatory shows that 10 types of cancer collectively comprise around two-thirds of new cases and deaths globally in 2022. Lung cancer was the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases. Female breast cancer ranked second (2.3 million cases, 11.6%), followed by #colorectalcancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970 000 cases, 4.9%).
This year’s theme for World Cancer Day is, “Closing the Care Gap”, alluding to the factors that can limit cancer care for vulnerable, unrepresented populations.
Read more
How does Evnia contribute to #cancerresearch?
- We are committed to the generation of real-world data and real-world evidence that facilitate market access to evidence-based, patient-centered, innovative medicines, in-vitro diagnostics, and companion diagnostics. Clinical trials and clinical investigations are critical for the validation of foundational research results. Evnia helps researchers translate their work into clinical evidence that can then be used for regulatory decision-making and reimbursement.
- We assist biotech and pharma manufacturers to maintain an efficient, dynamic post-market surveillance of their products ensuring timely reactions.
- We ensure that IVDs undergo a rigorous performance evaluation.
Join us when we share a few moments today to pay our respect to the ones gone but primarily to the ones still standing and fighting!
